Clinical trial
S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage…
NCT00109928 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00109928 |
|---|---|
| Title | S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma |
| Official title | Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (PEGS) in Peripheral T-Cell Non-Hodgkin's Lymphoma |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | cisplatin, etoposide, gemcitabine, methylprednisolone |
| Enrollment | 34 |
| Start date | Sep 1, 2005 |
| Primary completion | Jun 1, 2012 |
| Completion | Apr 1, 2014 |
| First posted | May 4, 2005 |
| Last update posted | Oct 1, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: